Insider Selling: Moderna Inc (NASDAQ:MRNA) CEO Sells 9,000 Shares of Stock

Share on StockTwits

Moderna Inc (NASDAQ:MRNA) CEO Stephane Bancel sold 9,000 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $82.00, for a total value of $738,000.00. Following the completion of the sale, the chief executive officer now directly owns 6,684,858 shares in the company, valued at $548,158,356. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Stephane Bancel also recently made the following trade(s):

  • On Friday, July 24th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $71.56, for a total value of $790,451.76.
  • On Wednesday, July 22nd, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $79.61, for a total value of $716,490.00.
  • On Monday, July 20th, Stephane Bancel sold 6,326 shares of Moderna stock. The stock was sold at an average price of $83.53, for a total value of $528,410.78.
  • On Thursday, July 16th, Stephane Bancel sold 19,000 shares of Moderna stock. The stock was sold at an average price of $83.92, for a total value of $1,594,480.00.
  • On Thursday, July 9th, Stephane Bancel sold 10,000 shares of Moderna stock. The stock was sold at an average price of $62.04, for a total value of $620,400.00.
  • On Monday, July 6th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $59.53, for a total value of $657,568.38.
  • On Wednesday, July 1st, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $62.92, for a total value of $566,280.00.
  • On Friday, June 26th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $60.65, for a total value of $669,939.90.
  • On Wednesday, June 24th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $63.25, for a total value of $569,250.00.
  • On Monday, June 22nd, Stephane Bancel sold 4,521 shares of Moderna stock. The stock was sold at an average price of $65.92, for a total value of $298,024.32.

Shares of NASDAQ MRNA opened at $74.10 on Friday. Moderna Inc has a 12 month low of $11.54 and a 12 month high of $95.21. The company has a market cap of $27.51 billion, a price-to-earnings ratio of -49.40 and a beta of 0.67. The business has a fifty day simple moving average of $69.03 and a 200-day simple moving average of $44.88.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.02. The business had revenue of $8.39 million during the quarter, compared to the consensus estimate of $18.17 million. Moderna had a negative return on equity of 37.49% and a negative net margin of 963.84%. Research analysts anticipate that Moderna Inc will post -1.41 earnings per share for the current fiscal year.

Several research analysts recently weighed in on the company. Zacks Investment Research raised Moderna from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a research note on Tuesday, July 21st. Needham & Company LLC assumed coverage on Moderna in a research note on Wednesday, July 15th. They set a “buy” rating and a $94.00 target price for the company. Roth Capital raised their target price on Moderna from $41.00 to $68.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Jefferies Financial Group assumed coverage on Moderna in a research note on Monday, July 13th. They set a “buy” rating and a $90.00 target price for the company. Finally, SunTrust Banks assumed coverage on Moderna in a research note on Monday, July 27th. They set a “buy” rating and a $120.00 target price for the company. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Moderna currently has an average rating of “Buy” and an average target price of $88.78.

A number of institutional investors have recently made changes to their positions in the stock. National Asset Management Inc. purchased a new stake in Moderna in the 2nd quarter worth about $699,000. Comerica Bank lifted its stake in Moderna by 26.1% in the 2nd quarter. Comerica Bank now owns 10,154 shares of the company’s stock worth $845,000 after acquiring an additional 2,102 shares in the last quarter. Wilbanks Smith & Thomas Asset Management LLC purchased a new stake in Moderna in the 2nd quarter worth about $211,000. Sigma Planning Corp lifted its stake in Moderna by 78.4% in the 2nd quarter. Sigma Planning Corp now owns 18,113 shares of the company’s stock worth $1,163,000 after acquiring an additional 7,958 shares in the last quarter. Finally, Flagship Harbor Advisors LLC lifted its stake in Moderna by 17.8% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 6,972 shares of the company’s stock worth $447,000 after acquiring an additional 1,051 shares in the last quarter. 52.09% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Read More: What is the CBOE Russell 2000® Volatility Index?

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nomura  Upgraded to “C” by TheStreet
Nomura Upgraded to “C” by TheStreet
TheStreet Upgrades Opko Health  to C-
TheStreet Upgrades Opko Health to C-
Graham  Stock Rating Reaffirmed by Maxim Group
Graham Stock Rating Reaffirmed by Maxim Group
First Commonwealth Financial  Rating Reiterated by DA Davidson
First Commonwealth Financial Rating Reiterated by DA Davidson
Oceaneering International’s  “Equal Weight” Rating Reiterated at Capital One Financial
Oceaneering International’s “Equal Weight” Rating Reiterated at Capital One Financial
O’Reilly Automotive’s  Outperform Rating Reiterated at William Blair
O’Reilly Automotive’s Outperform Rating Reiterated at William Blair


© 2006-2020 Ticker Report